ERBB2 and breast carcinoma: Increased HER2 expression in HER2-positive breast cancer (HER2+) cells causes loss of polarity and cell adhesion, leading to the onset of phosphorylation events and activation of TGFb/SMAD pathway through RAS signal cascade, increased signaling activities, and expression of HER2 variants2,3.